IBD: Vitamin D may stop the immune system from attacking gut bacteria

• Inflammatory bowel disease is a chronic disease in which the body’s immune system attacks the intestines.
• Research is ongoing into the best ways to manage inflammatory bowel disease, including medications and lifestyle changes.
• Results from a small study suggest that taking vitamin D may help people with inflammatory bowel disease, helping the body avoid attacking itself.

Inflammatory bowel disease (IBD) is a condition in which “the body’s immune system mistakenly causes the body’s immune system to attack healthy intestinal cells,” causing symptoms such as persistent fatigue, abdominal pain, chronic diarrhea, and unexplained weight loss. Centers for Disease Control and Prevention.

IBD These include subtypes of ulcerative colitis and Crohn’s disease, and patients with IBD may experience intermittent flare-ups of such symptoms.

recent study Published in cell report medicine They investigated how vitamin D supplementation affects IBD patients and found that increasing vitamin D levels may help the body’s immune system withstand gut bacteria.

The study involved 48 adult participants with ulcerative colitis or Crohn’s disease who also had low vitamin D levels. Researchers collected blood and stool samples from participants at baseline and again at the end of 12 weeks. Over the course of 12 weeks, participants received vitamin D weekly.

Researchers evaluated a number of factors, including disease activity, quality of life, and C-reactive protein in blood and stool samples. C-reactive protein Helps measure inflammation in the body.

The researchers also focused on noting two important points. Types of immunoglobulin:IgA and IgG. immunoglobulin A specific protein produced by certain white blood cells. IgA serves several beneficial functions in the digestive system, including regulating intestinal bacteria.

Researchers found that vitamin D had several positive effects on participants. They found that vitamin D helps “reset” and “rebalance” the communication between the immune system and the gut microbiome. The researchers explained that promoting this. immune toleranceas well as reducing inflammation.

Vitamin D supplementation also helped increase IgA levels, which are associated with a more stable immune response, and decrease immunoglobulin G (IgG) levels, which are associated with pro-inflammatory responses in the intestine.

After 12 weeks, participants’ disease activity scores also decreased. This means that participants feel better overall and have fewer or milder clinically significant symptoms. The researchers also observed a reduction in stool-based inflammatory markers.

“This study showed that 12 weeks of vitamin D supplementation resulted in improvements in patients as measured by disease activity scores and inflammatory markers. Vitamin D supplementation produces important changes in gut microbial composition that may also benefit the gut immune system,” said Stephen Cohn, MD, AGAF, FACG, chief of the Division of Gastroenterology and Hepatology at the University of Texas Medical Branch. According to research,.

Cristiano Panini, MD, consultant gastroenterologist and researcher at San Giovanni Addorolata Hospital in Rome, Italy, who was also not involved in the study, explained that the findings suggest that vitamin D may influence the interaction between the immune system and the gut microbiome in IBD.

“By combining microbiome and immune profiling, the authors suggest that vitamin D supplementation may shift the balance from a more inflammatory IgG-driven response to a more tolerogenic IgA-mediated response. This is an attractive concept because it frames IBD not only as excessive inflammation but also as a failure of immune tolerance to gut bacteria,” he said. Today’s medical news.

Professor Panini added that this study sheds light on a potential interaction mechanism between the vitamin D pathway and microbiota composition, which is consistent with recent hypotheses about the interaction, synergy, between vitamin D supplements and probiotics.

This study was relatively small and did not provide long-term data. Therefore, as research progresses, larger and longer-term studies may be helpful.

The researchers also acknowledged that the vitamin D administration was not based on a randomized process or compared to a placebo.

Professor Panini stressed the need for caution and that the clinical endpoint of this study was exploratory.

“Only serum vitamin D levels were considered; vitamin D receptor (VDR) expression and activation were not investigated,” he said.

Professor Panini also pointed out that the findings may be overextended and that larger, more controlled studies are needed.

“While the biological signals are strong, they have not yet translated into clear evidence of clinical benefit. As is often the case with advanced multi-omics research, there is a risk that mechanistic insights will be over-interpreted when applied to patient care,” he said.

Study author John Mark Gubatan, M.D., a gastroenterologist at the Mayo Clinic in Jacksonville, Fla., said the next steps in the research should explain the biological mechanisms behind how vitamin D acts in the gastrointestinal tract and address questions such as how much vitamin D patients with inflammatory bowel disease need.

“The highlights of our exploratory research are: [that] “Vitamin D may have potential benefits in regulating the interaction between the immune system and the gut microbiome in patients with IBD, and further research is needed to understand the precise vitamin D levels and vitamin D supplementation strategies that support this in patients with IBD and other chronic inflammatory diseases.”

“As a next step, we want to better understand whether some of the gut bacteria promoted by vitamin D can be used directly to improve inflammatory bowel disease, and understand how this works from an immune landscape perspective,” he continued.

“Furthermore, with this study we hope to better understand how vitamin D-induced increases in some of the B and T regulatory cells (immune cells that control inflammation) that migrate to the gastrointestinal tract may benefit IBD patients,” he added.

This study suggests potential benefits of vitamin D supplementation for IBD patients.

“The implications of this study for the care of patients with IBD are important. This study suggests that vitamin D supplementation may serve as a valuable adjunct to current advanced treatments for inflammatory bowel disease in this group,” said Professor Kohn.

Cohn also noted that more research is needed before making broad recommendations.

“Further research on the interaction of vitamin D supplementation with specific therapeutic agents for different disease subgroups is needed to clarify where vitamin D supplementation fits into current therapeutic approaches to treating patients with IBD,” he said.

Gubatan pointed out that current guidelines for vitamin D supplementation are based on bone health and calcium metabolism.

“Patients with chronic inflammation may have different needs for vitamin D. Patients with vitamin D deficiency should discuss nutritional supplementation with their health care provider and recheck levels according to current guidelines. It is premature to recommend measuring gut microbiota or immune markers to test vitamin D effectiveness.”
— Dr. John Mark Gubatan

“In fact, these findings confirm what clinicians are already doing: identifying and correcting vitamin D deficiency in patients with IBD. However, it would be premature to consider vitamin D as a sole treatment strategy,” Panini added.